Raltitrexed
DB00293
Approved Indication
For the treatment of malignant neoplasm of colon and rectum
2
Targets
0
Resistance Mutations
0
References
1HVY
Structure Loaded
Protein Targets
Mechanism of Action
Raltitrexed is an antineoplastic Agents and folic acid antagonists. Raltitrexed inhibits thymidylate synthase (TS) leading to DNA fragmentation and cell death. It is transported into cells via a reduced folate carrier. Inside the cell Raltitrexed is extensively polyglutamated, which enhances thymidylate synthase inhibitory power and duration. Inhibition of this enzyme results in decreased synthesis of thymidine triphosphate which is required for DNA synthesis.
Details
DrugBank ID
DB00293 ↗
Approval Date
—
Molecular Weight
458.488 g/mol
Drug Class
Other
ATC Codes
L01BA03
Synonyms
Raltitrexed
PubChem
CID: 104758 ↗
ChEMBL
CHEMBL225071 ↗
SMILES
CN(CC1=CC2=C(NC(C)=NC2=O)C=C1)C1=CC=C(S1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
ADMET Profile
Computing properties…